Merck

BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease.

Clinical immunology (Orlando, Fla.) (2015-04-07)
Phillip A Doerfler, Sushrusha Nayak, Roland W Herzog, Laurence Morel, Barry J Byrne
RESUMEN

Antibodies formed against the therapeutic protein are a life-threatening complication that arises during enzyme replacement therapy for Pompe disease (acid α-glucosidase deficiency; GAA). To provide an effective alternative to current practices, we investigated the capacity of anti-B-cell activating factor (BAFF) as a novel drug candidate to prevent antibody formation in a Pompe disease mouse model. A BAFF-neutralizing antibody was administered prophylactically and with maintenance doses in association with enzyme replacement therapy using recombinant human GAA in Gaa(-/-) mice. BAFF blockade delayed antibody production and increased GAA activity within tissues with protection from anaphylaxis. Anti-BAFF also resolved antibody formation during an immune response and precluded the maturation of antibody secreting cells from entering the bone marrow compartment. This treatment modality may therefore be a viable alternative for the clinical management of antibody formation for Pompe disease and has potential use against antibody formation in other protein replacement therapies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
IgG1, Kappa from murine myeloma, clone MOPC 21, purified immunoglobulin, buffered aqueous solution